Cargando…

Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma

Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) using the xenotransplantation limiting dilution assay (LDA). While TICs in clear cell renal cell carcinoma (ccRCC) appeared...

Descripción completa

Detalles Bibliográficos
Autores principales: Gedye, Craig, Sirskyj, Danylo, Lobo, Nazleen C., Meens, Jalna, Hyatt, Elzbieta, Robinette, Michael, Fleshner, Neil, Hamilton, Robert J, Kulkarni, Girish, Zlotta, Alexandre, Evans, Andrew, Finelli, Antonio, Jewett, Michael A. S., Ailles, Laurie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848484/
https://www.ncbi.nlm.nih.gov/pubmed/27121191
http://dx.doi.org/10.1038/srep25220
Descripción
Sumario:Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) using the xenotransplantation limiting dilution assay (LDA). While TICs in clear cell renal cell carcinoma (ccRCC) appeared rare in NOD/SCID/IL2Rγ(−/−) (NSG) mice, xenografts formed more efficiently from small tumour fragments, indicating the LDA underestimated ccRCC TIC frequency. Mechanistic interrogation of the LDA identified multiple steps that influence ccRCC TIC quantitation. For example, tissue disaggregation destroys most ccRCC cells, common assays significantly overestimate tumour cell viability, and microenvironmental supplementation with human extracellular factors or pharmacological inhibition of anoikis increase clonogenicity and tumourigenicity of ccRCC cell lines and primary tumour cells. Identification of these previously uncharacterized concerns that cumulatively lead to substantial underestimation of TICs in ccRCC provides a framework for development of more accurate TIC assays in the future, both for this disease and for other cancers.